Ω-agatoxin IVA, CAS No.rp174683, Gating inhibitor of Ca v2.1

Features and benefits
    Item Number
    rp174683
    Grouped product items
    SKUSizeAvailabilityPrice Qty
    rp174683-500μg
    500μg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $1,334.90
    rp174683-1mg
    1mg
    Available within 8-12 weeks(?)
    Production requires sourcing of materials. We appreciate your patience and understanding.
    $2,334.90
    View related series
    Cav2.1 Gating inhibitor

    Basic Description

    Product NameΩ-agatoxin IVA, CAS No.rp174683
    Synonymsomega-Aga-IVA;Omega-agatoxin-Aa4a
    GradeMoligand™
    Specifications & PurityMoligand™
    Action TypeGATING INHIBITOR
    Mechanism of actionGating inhibitor of Ca v2.1

    Associated Targets(Human)

    CACNA1A Tchem Voltage-dependent P/Q-type calcium channel subunit alpha-1A (0 Activities)
    Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

    Product Specifications

    CASrp174683

    Certificates

    Certificate of Analysis(COA)

    Enter Lot Number to search for COA:

    Genetic information

    Alternate Namesomega-Aga-IVA;Omega-agatoxin-Aa4a
    Reference
    • 1. Kinetics and inhibition of recombinant human cystathionine gamma-lyase. Toward the rational control of transsulfuration., The Journal of biological chemistry, Steegborn, C C and 7 more authors.
    • 2. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences., Proceedings of the National Academy of Sciences of the United States of America, Strausberg, Robert L RL and 83 more authors.
    • 3. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH)., Human genetics, Wang, Jian J and Hegele, Robert A RA.
    • 4. Cloning and nucleotide sequence of human liver cDNA encoding for cystathionine gamma-lyase., Biochemical and biophysical research communications, Lu, Y Y, O'Dowd, B F BF, Orrego, H H and Israel, Y Y.
    • 5. Single nucleotide polymorphism in CTH associated with variation in plasma homocysteine concentration., Clinical genetics, Wang, J J, Huff, A M AM, Spence, J D JD and Hegele, R A RA.
    • 6. Cystathionine gamma-lyase overexpression inhibits cell proliferation via a H2S-dependent modulation of ERK1/2 phosphorylation and p21Cip/WAK-1., The Journal of biological chemistry, Yang, Guangdong G, Cao, Kun K, Wu, Lingyun L and Wang, Rui R.
    • 7. The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)., Genome research, Gerhard, Daniela S DS and 115 more authors.
    • 8. Towards a proteome-scale map of the human protein-protein interaction network., Nature, Rual, Jean-François JF and 37 more authors.
    • 9. The DNA sequence and biological annotation of human chromosome 1., Nature, Gregory, S G SG and 178 more authors.
    • 10. Polymorphisms in one-carbon metabolism and trans-sulfuration pathway genes and susceptibility to bladder cancer., International journal of cancer, Moore, Lee E LE and 14 more authors. more

    Related Documents

    References

    1. Christopoulos A, Changeux JP, Catterall WA, Fabbro D, Burris TP, Cidlowski JA, Olsen RW, Peters JA, Neubig RR, Pin JP et al..  (2014)  International union of basic and clinical pharmacology. XC. multisite pharmacology: recommendations for the nomenclature of receptor allosterism and allosteric ligands..  Pharmacol Rev,  66  (4): (918-47).  [PMID:25026896]

    Solution Calculators